Your browser doesn't support javascript.
loading
Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2.
Zhang, Haikuo; Fillmore Brainson, Christine; Koyama, Shohei; Redig, Amanda J; Chen, Ting; Li, Shuai; Gupta, Manav; Garcia-de-Alba, Carolina; Paschini, Margherita; Herter-Sprie, Grit S; Lu, Gang; Zhang, Xin; Marsh, Bryan P; Tuminello, Stephanie J; Xu, Chunxiao; Chen, Zhao; Wang, Xiaoen; Akbay, Esra A; Zheng, Mei; Palakurthi, Sangeetha; Sholl, Lynette M; Rustgi, Anil K; Kwiatkowski, David J; Diehl, J Alan; Bass, Adam J; Sharpless, Norman E; Dranoff, Glenn; Hammerman, Peter S; Ji, Hongbin; Bardeesy, Nabeel; Saur, Dieter; Watanabe, Hideo; Kim, Carla F; Wong, Kwok-Kin.
Afiliação
  • Zhang H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
  • Fillmore Brainson C; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Koyama S; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital Boston, Boston, Massachusetts 02115, USA.
  • Redig AJ; Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Chen T; Harvard Stem Cell Institute, Cambridge, Massachusetts 02138, USA.
  • Li S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
  • Gupta M; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Garcia-de-Alba C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
  • Paschini M; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Herter-Sprie GS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
  • Lu G; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Zhang X; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
  • Marsh BP; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Tuminello SJ; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital Boston, Boston, Massachusetts 02115, USA.
  • Xu C; Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Chen Z; Harvard Stem Cell Institute, Cambridge, Massachusetts 02138, USA.
  • Wang X; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital Boston, Boston, Massachusetts 02115, USA.
  • Akbay EA; Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Zheng M; Harvard Stem Cell Institute, Cambridge, Massachusetts 02138, USA.
  • Palakurthi S; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital Boston, Boston, Massachusetts 02115, USA.
  • Sholl LM; Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Rustgi AK; Harvard Stem Cell Institute, Cambridge, Massachusetts 02138, USA.
  • Kwiatkowski DJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
  • Diehl JA; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Bass AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
  • Sharpless NE; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Dranoff G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
  • Hammerman PS; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Ji H; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital Boston, Boston, Massachusetts 02115, USA.
  • Bardeesy N; Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.
  • Saur D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
  • Watanabe H; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
  • Kim CF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
  • Wong KK; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Nat Commun ; 8: 14922, 2017 04 07.
Article em En | MEDLINE | ID: mdl-28387316
ABSTRACT
Adenosquamous lung tumours, which are extremely poor prognosis, may result from cellular plasticity. Here, we demonstrate lineage switching of KRAS+ lung adenocarcinomas (ADC) to squamous cell carcinoma (SCC) through deletion of Lkb1 (Stk11) in autochthonous and transplant models. Chromatin analysis reveals loss of H3K27me3 and gain of H3K27ac and H3K4me3 at squamous lineage genes, including Sox2, ΔNp63 and Ngfr. SCC lesions have higher levels of the H3K27 methyltransferase EZH2 than the ADC lesions, but there is a clear lack of the essential Polycomb Repressive Complex 2 (PRC2) subunit EED in the SCC lesions. The pattern of high EZH2, but low H3K27me3 mark, is also prevalent in human lung SCC and SCC regions within ADSCC tumours. Using FACS-isolated populations, we demonstrate that bronchioalveolar stem cells and club cells are the likely cells-of-origin for SCC transitioned tumours. These findings shed light on the epigenetics and cellular origins of lineage-specific lung tumours.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Adenocarcinoma / Proteínas Serina-Treonina Quinases / Complexo Repressor Polycomb 2 / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Escamosas / Adenocarcinoma / Proteínas Serina-Treonina Quinases / Complexo Repressor Polycomb 2 / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2017 Tipo de documento: Article